INVESTORS & MEDIA
News Release
Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
First Phase 2 data for odronextamab (CD20xCD3) in diffuse large B-cell lymphoma and follicular lymphoma to be presented in two oral sessions
Additional presentations include new data on linvoseltamab (REGN5458; BCMAxCD3) in multiple myeloma
Regeneron will host an investor webcast on
"We've made significant strides toward developing a comprehensive hematology portfolio that has the potential to address diverse and difficult-to-treat blood cancers and blood disorders," said L. Andres Sirulnik, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Hematology at Regeneron. "Our ASH presentations not only showcase some of the many modalities we're exploring – which includes monoclonal antibodies, bispecific antibodies, gene modifying technologies, and siRNA inhibition – but also the depth of research we're conducting in support of our pipeline."
Notable Regeneron blood cancer presentations at ASH include the first interim data from the Phase 2 ELM-2 study of odronextamab (CD20xCD3) in relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), which will be shared in two oral sessions. Updated Phase 1/2 data will also be presented for linvoseltamab (REGN5458; BCMAxCD3 bispecific antibody) in patients with heavily pre-treated multiple myeloma. Based on these findings, a recommended dose was selected for the Phase 2 portion of the linvoseltamab trial.
Additionally, first clinical data from two Phase 2 studies evaluating pozelimab (C5 antibody) in combination with Alnylam Pharmaceuticals, Inc.'s cemdisiran (siRNA C5 inhibitor) in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder, will be shared.
Investor Webcast Information
Regeneron will host a conference call and simultaneous webcast to share updates on the company's hematology portfolio on
Regeneron data at ASH:
Abstract title |
Abstract |
Presentation |
Odronextamab |
||
Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal Phase II study ELM-2
|
#444 Oral Presentation
|
|
Odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) Grade 1–3a: Results from a prespecified analysis of the pivotal Phase II study ELM-2
|
#949 Oral Presentation
|
R06-R09
|
Trial in Progress: Follicular lymphoma outcomes in relapsed/refractory patients treated with systemic therapy in a real-world assessment (FLORA)
|
#2277 Poster Presentation
|
Hall D
|
Trial in Progress: Outcomes in patients with relapsed/refractory DLBCL treated with systemic therapy from real-world experience (ORCHID)
|
#3601 Poster Presentation
|
Hall D
|
Selection of odronextamab pediatric dosing regimens for aggressive non-Hodgkin lymphoma via a modeling and simulation approach
|
#3992 Poster Presentation
|
Hall D
|
Optimization of intravenous Odronextamab step-up dosing regimen for reducing the risk of high-grade cytokine release syndrome |
#5245 Publication Number |
Online publication |
Modeling and simulation in support of odronextamab subcutaneous dose selection for adult patients with indolent or aggressive non-Hodgkin lymphoma |
#5257 Publication Number |
Online publication |
Evaluate dynamics of IL-6 release during step-up dosing of subcutaneous administration of odronextamab via a quantitative systems pharmacology modelling approach |
#5424 Publication Number |
Online publication |
A quantitative systems pharmacology modelling framework for evaluation of cytokine release syndrome mediated by intravenous odronextamab monotherapy in patients with B-cell non-Hodgkin lymphoma |
#5433 Publication Number |
Online publication |
Linvoseltamab (formerly REGN5458) |
||
Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed/refractory multiple myeloma: A Phase 1/2 first-in-human study
|
#4555 Poster Presentation
|
Hall D
|
Trial in Progress: REGN5458, a BCMAxCD3 bispecific antibody, in a Phase Ib multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma
|
#1936 Poster Presentation
|
Hall D
|
Trial in Progress: A Phase II window of opportunity study of the BCMAxCD3 bispecific antibody REGN5458 in previously untreated patients with symptomatic multiple myeloma
|
#4551 Poster Presentation
|
Hall D
|
Real-world study of patients with triple-class exposed relapsed or refractory multiple myeloma: Analysis across a spectrum of advanced disease stage patients in the
|
#2321 Poster Presentation
|
Hall D
|
Prevalence of ocular comorbidities in elderly patients with multiple myeloma in the
|
#2310 Poster Presentation
|
Hall D
|
Incidence of second primary malignancies (SPMs) in patients in the
|
#4896 Poster Presentation
|
Hall D
|
Pozelimab + Cemdisiran |
||
Long-term efficacy and safety of pozelimab monotherapy in patients with paroxysmal nocturnal hemoglobinuria
|
#2326 Poster Presentation
|
Hall D
|
A Phase 2, randomized trial evaluating the safety and efficacy of pozelimab and cemdisiran in patients with paroxysmal nocturnal hemoglobinuria
|
#3651 Poster Presentation
|
Hall D
|
Patient-reported outcomes from a Phase 2, randomized trial evaluating the safety and efficacy of pozelimab and cemdisiran in patients with paroxysmal nocturnal hemoglobinuria
|
#4873 Poster Presentation
|
Hall D
|
A Phase 2, open-label study evaluating the safety and efficacy of combination pozelimab and cemdisiran therapy in patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab
|
#3652 Poster Presentation
|
Hall D
|
REGN7257 (IL-2Rg antibody) |
||
Blockade of common gamma chain cytokine signaling with REGN7257, an interleukin 2 receptor gamma (IL2RG) monoclonal antibody, protected mice from inflammatory and autoimmune diseases
|
#194 Oral Presentation
|
260-262
|
Evaluation of common gamma chain cytokine signaling blockade with REGN7257, an interleukin 2 receptor gamma (IL2RG) monoclonal antibody, on immune cell populations in monkey and human
|
#1249 Poster Presentation
|
Hall D
|
The potential uses of odronextamab, linvoseltamab, pozelimab, cemdisiran and REGN7257 described above are investigational, and their safety and efficacy have not been fully evaluated by any regulatory authority.
About Regeneron in Hematology
At Regeneron, we're applying more than three decades of biology expertise with our proprietary VelociSuite® technologies to develop medicines for patients with diverse blood cancers and rare blood disorders.
Our blood cancer research is focused on bispecific antibodies that are being investigated both as monotherapies and in combination with each other and emerging therapeutic modalities. Together, they provide us with unique combinatorial flexibility to develop customized and potentially synergistic cancer treatments.
Our research and collaborations to develop potential treatments for rare blood disorders include explorations in antibody medicine, gene editing and gene-knockout technologies, and investigational RNA-approaches focused on depleting abnormal proteins or blocking disease-causing cellular signaling.
If you are interested in learning more about our clinical trials, please contact us (clinicaltrials@regeneron.com or 844-734-6643) or visit our clinical trials website.
About Regeneron's VelocImmune Technology
Regeneron's VelocImmune® technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer
About Regeneron
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.
For more information, please visit www.Regeneron.com or follow @Regeneron on Twitter.
Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
Contacts: |
|
Media Relations |
Investor Relations |
Taylor Ramsey |
|
Tel: +1 914-409-2381 |
Tel: +1 914-847-3482 |
View original content:https://www.prnewswire.com/news-releases/regeneron-presents-new-data-at-ash-from-advancing-hematology-pipeline-across-multiple-blood-cancers-and-disorders-301666938.html
SOURCE